Literature DB >> 29020313

Trends in Invasive Pneumococcal Disease in Cancer Patients After the Introduction of 7-valent Pneumococcal Conjugate Vaccine: A 20-year Longitudinal Study at a Major Urban Cancer Center.

Yeon Joo Lee1,2, Yao-Ting Huang1, Seong Jin Kim1, Marina Kerpelev3, Victoria Gonzalez1, Anna Kaltsas1,2, Genovefa Papanicolaou1,2.   

Abstract

Background: Rates of invasive pneumococcal disease (IPD) declined since routine childhood immunization with the 7-valent pneumococcal conjugate vaccine (PCV7) in 2000. We studied the impact of PCV7 on the incidence of IPD in cancer patients.
Methods: This was a retrospective analysis of adult and pediatric patients treated at Memorial Sloan Kettering Cancer Center from 1992 to 2012. Recovery of Streptococcus pneumoniae from a sterile site defined IPD. IPD incidence was calculated as cases per 1,000 unique patient-visits per year (UPV). IPD incidence was calculated for the periods: "before PCV7" (1992-2000), "after PCV7" (2001-2010) and "after PCV13" (2011-2012).
Results: Of 343 IPD cases, 165, 155, and 23 cases occurred "before PCV7," "after PCV7" and "after PCV13" respectively. The IPD incidence declined from 0.43 "before PCV7" to 0.17 "after PCV7" (95% confidence interval [CI]: 0.33-0.46, P < .001) and 0.11 "after PCV13" (95% CI: 0.42-0.96, P = .004). Adults with hematologic malignancies and children had the highest incidence. In patients 1-4 years old, the incidence declined from 11.2 "before PCV7" to 2.38 "after PCV7" (79% decrease, 95% CI: 0.1-0.4, P < .001). In patients with hematologic malignancies, the incidence declined from 2.55 "before PCV7" to 0.92 "after PCV7" (64% decrease, 95% CI: 0.27-0.47, P < .001). Conclusions: The incidence of IPD among cancer patients sharply declined after introduction of PCV7; especially in high risk groups. The decline in adults suggests an indirect effect from PCV7 childhood vaccination.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cancer; invasive pneumococcal disease; pneumococcal conjugate vaccine

Mesh:

Substances:

Year:  2018        PMID: 29020313      PMCID: PMC5850633          DOI: 10.1093/cid/cix739

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  33 in total

1.  Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies.

Authors:  Gunjan L Shah; Leyla Shune; Duncan Purtill; Sean Devlin; Emily Lauer; Marissa Lubin; Valkal Bhatt; Courtney McElrath; Nancy A Kernan; Andromachi Scaradavou; Sergio Giralt; Miguel A Perales; Doris M Ponce; James W Young; Monica Shah; Genovefa Papanicolaou; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-10       Impact factor: 5.742

2.  Carriage of pneumococci after pneumococcal vaccination.

Authors:  S K Obaro; R A Adegbola; W A Banya; B M Greenwood
Journal:  Lancet       Date:  1996-07-27       Impact factor: 79.321

3.  Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs.

Authors:  Altynay Shigayeva; Wallis Rudnick; Karen Green; Danny K Chen; Walter Demczuk; Wayne L Gold; Jennie Johnstone; Ian Kitai; Sigmund Krajden; Reena Lovinsky; Matthew Muller; Jeff Powis; Neil Rau; Sharon Walmsley; Gregory Tyrrell; Ari Bitnun; Allison McGeer
Journal:  Clin Infect Dis       Date:  2015-09-09       Impact factor: 9.079

4.  Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States.

Authors:  Jennifer B Rosen; Ann R Thomas; Catherine A Lexau; Art Reingold; Jim L Hadler; Lee H Harrison; Nancy M Bennett; William Schaffner; Monica M Farley; Bernard W Beall; Matt R Moore
Journal:  Clin Infect Dis       Date:  2011-07-15       Impact factor: 9.079

5.  Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.

Authors:  Matthew R Moore; Ruth Link-Gelles; William Schaffner; Ruth Lynfield; Catherine Lexau; Nancy M Bennett; Susan Petit; Shelley M Zansky; Lee H Harrison; Arthur Reingold; Lisa Miller; Karen Scherzinger; Ann Thomas; Monica M Farley; Elizabeth R Zell; Thomas H Taylor; Tracy Pondo; Loren Rodgers; Lesley McGee; Bernard Beall; James H Jorgensen; Cynthia G Whitney
Journal:  Lancet Infect Dis       Date:  2015-02-03       Impact factor: 25.071

6.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

7.  Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: implications for vaccine strategies.

Authors:  Manel Luján; Joaquín Burgos; Miguel Gallego; Vicenç Falcó; Guadalupe Bermudo; Anna Planes; Dionisia Fontanals; Maddalena Peghin; Eduard Monsó; Jordi Rello
Journal:  Clin Infect Dis       Date:  2013-09-24       Impact factor: 9.079

8.  Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease.

Authors:  B Frederiksen; L Specht; J Henrichsen; F K Pedersen; J Pedersen-Bjergaard
Journal:  Eur J Haematol       Date:  1989-07       Impact factor: 2.997

9.  Invasive pneumococcal disease in patients with haematological malignancies before routine use of conjugate vaccines in Finland.

Authors:  Vesa Lindström; Janne Aittoniemi; Outi Lyytikäinen; Peter Klemets; Jukka Ollgren; Raija Silvennoinen; J Pekka Nuorti; Marjatta Sinisalo
Journal:  Infect Dis (Lond)       Date:  2015-12-04

10.  Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report.

Authors:  Marcin Pasiarski; Jacek Rolinski; Ewelina Grywalska; Agnieszka Stelmach-Goldys; Izabela Korona-Glowniak; Stanislaw Gozdz; Iwona Hus; Anna Malm
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

View more
  3 in total

Review 1.  Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient.

Authors:  Mini Kamboj; Monika K Shah
Journal:  Infect Dis Clin North Am       Date:  2019-06       Impact factor: 5.982

2.  Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Medically At-Risk Children in Australia: A Record Linkage Study.

Authors:  Alamgir Kabir; Anthony T Newall; Deborah Randall; Hannah C Moore; Sanjay Jayasinghe; Parveen Fathima; Bette Liu; Peter McIntyre; Heather F Gidding
Journal:  J Pediatric Infect Dis Soc       Date:  2022-09-29       Impact factor: 5.235

3.  Invasive pneumococcal disease in children with cancer: Incidence density, risk factors and isolated serotypes.

Authors:  Pedro Mendes Lages; Fabianne Carlesse; Bruno Cruz Boettger; Antônio Carlos Campos Pignatari; Antônio Sérgio Petrilli; Maria Isabel de Moraes-Pinto
Journal:  Braz J Infect Dis       Date:  2020-10-23       Impact factor: 3.257

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.